You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

177Lu-DOTA-JR11

Showing 1 - 25 of 1,844
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors Trial in New York (PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11)

Completed
Has Results
  • Neuroendocrine Tumors
  • PET/CT Imaging
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2022

Meningioma Trial in Basel (177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and

Recruiting
  • Meningioma
  • 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
  • +2 more
  • Basel, Basel-Stadt, Switzerland
    University Hospital Basel, Department of Neurosurgery
Aug 2, 2021

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Refractory Solid Tumor Trial in Xiamen (177Lu-DOTA-EB-FAPI radionuclide therapy)

Recruiting
  • Refractory Solid Tumor
  • 177Lu-DOTA-EB-FAPI radionuclide therapy
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 26, 2023

Glioblastoma Trial in France, Portugal, Spain ([177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide)

Recruiting
  • Glioblastoma
  • Bron, France
  • +8 more
Jan 23, 2023

Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

Recruiting
  • Refractory Thyroid Gland Carcinoma
  • +3 more
  • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 3, 2022

Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor Trial (procedure, drug, other)

Not yet recruiting
  • Metastatic Midgut Neuroendocrine Tumor
  • Unresectable Midgut Neuroendocrine Tumor
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Mar 16, 2023

Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Lille, France
  • +6 more
Jan 23, 2023

Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma Trial in Sacramento ([68Ga]Ga DOTA-5G and [177Lu]Lu

Recruiting
  • Metastatic Pancreatic Cancer
  • Locally Advanced Pancreatic Adenocarcinoma
  • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
  • Sacramento, California
    University of California Davis
Apr 21, 2022

Metastatic Prostate Cancer Trial in Perth (177Lu-DOTA-rosopatamb)

Not yet recruiting
  • Metastatic Prostate Cancer
  • 177Lu-DOTA-rosopatamb
  • (no location specified)
Aug 29, 2022

Metastatic Malignant Tumor in the Viscera, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic

Not yet recruiting
  • Metastatic Malignant Neoplasm in the Viscera
  • +4 more
  • Lutetium Lu 177 Dotatate
  • (no location specified)
Jan 25, 2023

SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • SCLC
  • +2 more
  • GD2-SADA:177Lu-DOTA Complex
  • (no location specified)
May 4, 2022

Neuroendocrine Tumors Trial in New York (177Lu-DOTA-EB-TATE, Amino Acid Solution)

Recruiting
  • Neuroendocrine Tumors
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 22, 2022

Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)

Not yet recruiting
  • Metastatic Neuroendocrine Tumor
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Feb 10, 2023

Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma Trial in Rochester (radiation, drug, procedure, other)

Recruiting
  • Grade 1 Meningioma
  • +4 more
  • Gallium Ga 68-DOTATATE
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 11, 2023

Neuroendocrine Tumors Trial in Beijing (Lutetium[177Lu] Oxodotreotide Injection)

Not yet recruiting
  • Neuroendocrine Tumors
  • Lutetium[177Lu] Oxodotreotide Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 30, 2023

Neuroblastoma Trial in Lille, Lyon, Toulouse (PRRT with 177Lu-DOTATATE)

Not yet recruiting
  • Neuroblastoma
  • PRRT with 177Lu-DOTATATE
  • Lille, France
  • +2 more
Nov 8, 2022

Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Tumor, Stage III Pancreatic Neuroendocrine Tumor AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Neuroendocrine Tumor
  • +4 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jan 14, 2023

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • 89Zr-TLX250
  • 177Lu-TLX250 and Peposertib
  • North Ryde, New South Wales, Australia
  • +4 more
May 22, 2023

Neuroendocrine Tumor Trial in United States (Lutetium Lu 177 Dotatate, Peposertib)

Recruiting
  • Neuroendocrine Neoplasm
  • Biospecimen Collection
  • +4 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)

Active, not recruiting
  • Neuroendocrine Carcinoma
  • Lu-DOTA-TATE
  • London, Ontario, Canada
    London Health Sciences Centre
Apr 5, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Metastatic Prostate Cancer Trial in Perth (177Lu-DOTA-TLX591)

Not yet recruiting
  • Metastatic Prostate Cancer
  • 177Lu-DOTA-TLX591
  • Perth, Western Australia, Australia
  • +1 more
Nov 25, 2021

Patients With Metastatic Castration-resistant Prostate Cancer Trial (177Lu-PSMA-617 PET scan)

Not yet recruiting
  • Patients With Metastatic Castration-resistant Prostate Cancer
  • 177Lu-PSMA-617 PET scan
  • (no location specified)
Nov 13, 2023

Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,

Recruiting
  • Advanced Lung Carcinoid Tumor
  • +11 more
  • Boston, Massachusetts
  • +1 more
Jul 19, 2022